Hepatitis News and Research

RSS

Infectious diseases pose a serious threat to the nation's public health

Infectious diseases pose a serious threat to the nation's public health. Today, experts addressed key developments to the current and future outlook of infectious diseases, highlighting adolescent immunizations, outbreaks and epidemics of infectious diseases, antimicrobial resistance and new developments in HIV medicine, at a press conference sponsored by the National Foundation for Infectious Diseases (NFID).

27 Jul 2005

Steady upward climb in child vaccinations

According to U.S. health officials, a record high rate of 81 percent of toddlers 19 months to 3 years old are now getting vaccinated with the full recommended series.

27 Jul 2005

Molecular link between a viral infection and development of a common and fatal form of liver cancer

Researchers at The University of Texas M. D. Anderson Cancer Center have uncovered a crucial molecular link between a viral infection and development of a common and fatal form of liver cancer. In the process, they have identified a possible way to treat this disease as well as a number of other cancers.

26 Jul 2005

Acetaminophen, when taken as directed, is safe for patients with liver disease

Contrary to common perception, clinical data demonstrate that acetaminophen is an appropriate pain relief choice for patients with chronic liver disease. According to a systematic literature review of the data, which is published in the current issue of the American Journal of Therapeutics, there is no evidence that acetaminophen at therapeutic doses aggravates liver disease.

26 Jul 2005

Crucial molecular link between a hepatitis B virus (HBV) and hepatocellular carcinoma (HCC)

21 Jul 2005

Biological breakthrough that could offer new hope in the fight against liver cancer

Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.

21 Jul 2005

Combination of ribavirin and interferon is more effective in treating hepatitis C than using interferon alone

The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.

19 Jul 2005

Targeted program drastically reduced hepatitis A in U.S.

According to a newly released study, the number of cases of hepatitis A have fallen by 76 percent in the United States since a vaccination campaign targeted children in communities with the highest rates of the disease.

13 Jul 2005

Sirna Therapeutics granted new UK patents

Sirna Therapeutics has announced that the United Kingdom (UK) Patent Office has granted the Company two additional short interfering RNA (siRNA) target patents. The first patent covers any siRNA with one or more chemical modifications targeting Vascular Endothelial Growth Factor (VEGF).

12 Jul 2005

RxKinetix receives grant to develop thermostable vaccines with improved stability at non-refrigerated temperatures

RxKinetix Inc., a specialty pharmaceutical company has received a grant offer from the prestigious Grand Challenges in Global Health initiative. The grant will be used to develop thermostable vaccines with improved stability at non-refrigerated temperatures for use in the world's poorest countries.

30 Jun 2005

Studies compare hepatitis B drugs

According to a new study Roche's brand of interferon can help control the potentially deadly liver infection, hepatitis B, better than a competitor's drug.

30 Jun 2005

Office-based buprenorphine treatment for drug abuse shows promise

Patients who receive buprenorphine treatment for opioid addiction in an office-based setting are more likely than those receiving methadone treatment to be young men, new to drug use, and with no history of methadone treatment, Yale School of Medicine researchers report in a study published in Drug and Alcohol Dependence.

28 Jun 2005

Vaccine against Lassa fever works in monkeys

Scientists say that a genetically engineered virus may possibly offer the first effective vaccine against Lassa fever.

28 Jun 2005

Metabasis and Merck collaborate to develop new treatment for diabetes, hyperlipidemia and obesity

Metabasis Therapeutics and Merck announced today that they have formed a collaboration to research, develop and commercialize novel small molecule therapeutics with potential to treat several diseases, including type II diabetes, hyperlipidemia and obesity, by activation of an enzyme in the liver called AMP-activated Protein Kinase (AMPK).

27 Jun 2005

3 health workers arrested after hepatitis vaccine kills a schoolchild and makes 120 others ill

After a hepatitis vaccine was administered in their schools in central China, one child died and another 120 have become ill.

27 Jun 2005

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

Leading medical experts from throughout the UK will be gathering in Edinburgh today and tomorrow (21-22 April 2004) to arrive at a consensus on how best to treat and manage the 'silent epidemic' of hepatitis C - a virus which is estimated to be carried by over 400,000 people in the UK and which continues to spread globally, as the majority of carriers do not realise they have been infected.

21 Jun 2005

Hepatitis News and Research

Infectious diseases pose a serious threat to the nation's public health

Steady upward climb in child vaccinations

Molecular link between a viral infection and development of a common and fatal form of liver cancer

Acetaminophen, when taken as directed, is safe for patients with liver disease

Crucial molecular link between a hepatitis B virus (HBV) and hepatocellular carcinoma (HCC)

Biological breakthrough that could offer new hope in the fight against liver cancer

Combination of ribavirin and interferon is more effective in treating hepatitis C than using interferon alone

Targeted program drastically reduced hepatitis A in U.S.

Sirna Therapeutics granted new UK patents

RxKinetix receives grant to develop thermostable vaccines with improved stability at non-refrigerated temperatures

Studies compare hepatitis B drugs

Office-based buprenorphine treatment for drug abuse shows promise

Vaccine against Lassa fever works in monkeys

Metabasis and Merck collaborate to develop new treatment for diabetes, hyperlipidemia and obesity

3 health workers arrested after hepatitis vaccine kills a schoolchild and makes 120 others ill

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

Buprenorphine treatment for opioid addiction shows promise

New Zealand moves to routinely offering antenatal HIV screening

'Hazardous' drinking and drug use are much less severe but much more common than dependence

When in Russia, drink vodka

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News